“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Sunday, August 31, 2025

Braeburn


Braeburn products


BRIXADI®

  • Generic: buprenorphine extended-release injection (subcutaneous)

  • Indication: moderate to severe opioid use disorder (OUD) in patients already initiated on or transitioning from transmucosal buprenorphine

  • Usage / Dosing: administered by healthcare providers; available in weekly and monthly dosing schedules via subcutaneous injection

Probuphine®

  • Generic: buprenorphine implant

  • Indication: maintenance treatment of opioid addiction (for clinically stable patients already on low-dose transmucosal buprenorphine)

  • Usage / Dosing: healthcare provider inserts four small implants under the skin of the upper arm; designed to deliver consistent medication over six months

Investigational Pipeline Products

  • CAM2038 – weekly and monthly subcutaneous injectable depot of buprenorphine (investigated for OUD and chronic pain)

  • BB0417 – injectable combining buprenorphine with granisetron for acute pain

  • BB0817 – six-month risperidone implant being studied for schizophrenia



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)